Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O9UN
|
|||
| Former ID |
DNCL002043
|
|||
| Drug Name |
SAR231893
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 3 | [1] | |
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 3 | [1] | ||
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 4 receptor alpha (IL4R) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| IL4-mediated signaling events | ||||
| WikiPathways | Inflammatory Response Pathway | |||
| IL-4 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02134028) Long-Term Safety Evaluation of Dupilumab in Patients With Asthma. U.S. National Institutes of Health. | |||
| REF 2 | Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. | |||
| REF 3 | ClinicalTrials.gov (NCT02277769) Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.